Phase II Chemoprevention Trial with High Dose Fenretinide for Oral Pre-Malignant Lesions

BACKGROUND: In a previous phase II trial, we demonstrated that fenretinide 200 mg/day had limited activity in retinoid-refractory leukoplakia (34% response rate), possibly due to the lack of achievement of high serum levels which would be required to elicit retinoid-receptor independent apoptosis in...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: William, William N., Lee, J. Jack, Lippman, Scott M., Martin, Jack W., Tran, Hai T., Sabichi, Anita L., Kim, Edward S., Feng, Lei, Papadimitrakopoulou, Vassiliki A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4161148/
https://ncbi.nlm.nih.gov/pubmed/19139014
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-08-0100
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky